Please Join Us. International Psychogeriatric Association. Dependency Ratio. Geriatric Psychiatry in the 21st Century: A Global Perspective
|
|
- Blaise Bryan
- 5 years ago
- Views:
Transcription
1 International Psychogeriatric Association Please Join Us Geriatric Psychiatry in the 21st Century: A Global Perspective Jacobo Mintzer M.D. Executive Director Roper Saint Frances Clinical and Biotechnology Research Institute Professor of Health Sciences Medical University of South Carolina and Staff Physician Ralph P Johnson Veterans Medical Center, Charleston S.C. USA Past President International Psychogeroatric Association 1 Percentage of Growth for People Over 65 Years of Age Dependency Ratio Source: Dept for work and Pensions UK Source: National Bank Denmark The dependency ratio measures the % of dependent people (not of working age) / number of people of working age (economically active)
2 EURO GDP Balancing Budgets? Increase in Health Care Costs More Issues of Concern Most countries do not have a structured training in geriatric mental health in any discipline Most countries do not have a public policy agenda in geriatric mental health NO country has the resources to manage geriatric mental health needs
3 A Concrete Example Eli Lilly s Solanezumab will earn Decision Resources Proprietary Clinical Gold Standard Status for the treatment of Mild to Moderate Alzheimer s Disease. The total Alzheimer s Disease Drug Market will nearly triple, increasing from $5.4 Billion in 2010 to $14.4 Billion in 2020, according to findings from Decision Resources Christopher Comfort Decision Resources Group ccomfort@dresources.com 10 Memantine in Moderate to Severe AD Study Results: Cognition SIB The Solution is in the Spaghetti The Memantine Group Exhibited Significantly Superior Cognitive Function Compared With the Placebo Group Mean Change From Baseline in SIB Score P=.068 Memantine Placebo P<.001 P=.002 P< End Point Week n = n = OC analysis. LOCF analysis Adapted with permission 2004 from: Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. N Engl J Med. 2003;348: Copyright 2003 Massachusetts Medical Society. All rights reserved. Improvement Deterioration
4 The Solution is in the Spaghetti The Vision of a Futurist The 21st century will be about massively providing highly individualized products. Ted Gordon AAGP 2000 The Geriatric Mental Heath Hypothesis The impact of Pharmacogenetics and Biomedical Research in Clinical Practice The challenge for geriatric mental health in the 21st century is to provide care for the many with attention for the individual We need to provide massive amounts of individualized care Without breaking the bank!!! Drug discovery research Identify new disease susceptibility genes Identify new disease mechanisms Identify new therapeutic targets Drug development Stratification of disease Select patients most subgroups (better diagnosis) suited to therapies Correlate genotype with disease progression Correlate genotype with drug efficacy, safety and metabolism (dosage) Predict responders and non-responders to a drug Drug marketing Cost effective health care management
5 What Do I Mean? Risperdal in the treatment of psychosis and aggressive behavior in dementia The average risk to develop a stroke or a cardiovascular condition over a ten year period for a 57 years old man is 7.4% The use of Cholesterol lowering treatments can reduce the risk by 30% or over 2 points. The medications however have potential severe side effects My personal risk is 2.4%. In my case, even if I had high cholesterol, the treatment will only reduce my risk by 0.8 points. Mean change from baseline BEHAVE-AD Aggressiveness Score Weeks of therapy Endpoint Katz, Jeste, Mintzer et al. J Clin Psychiatry 1999; 60: Risperidone in the treatment of psychosis and aggressive behaviour in dementia: % of patients with adverse events FDA Warning Events (>10%) EPS Somnolence Agitation Falls Edema, peripheral Injury Pain Placebo n= mg/d n= mg/d n= mg/d n= An FDA meta-analysis of 17 placebocontrolled clinical trials (n=5,106) of 4 atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in elderly patients with dementia-related psychosis revealed a pooled 4.5% incidence of mortality for atypical antipsychotics versus 2.6% for placebo Katz, Jeste, Mintzer et al. J Clin Psychiatry 1999; 60: FDA April, 2005
6 Risperidone in the treatment of psychosis of Alzheimer s disease: Results from a prospective clinical trial CATIE Mean (± SE) change from baseline over time in BEHAVE-AD Psychosis subscale score. Pla = placebo; Ris = risperidone; SE = Standard Error. Mintzer,2006 Schneider, L 2006 Mean Efficacy Behave-AD Over Time Low-agitation Placebo High-agitation Placebo Low-agitation Risperidone High-agitation Risperidone 6 Baseline Endpoint Time (Weeks) Mintzer, APA AGT:P < 0.05 vs. Placebo Non-AG: P< 0.05 vs. Placebo. Dementia CMAI Scores: High and Low Agitation Groups Mintzer J et al. ACNP 2005.
7 Adverse Events By Level of agitation Mintzer J et al. ACNP 2005 The Antipsychotic Discontinuation in Alzheimer Disease Trial Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation Current available regulations require antipsychotic discontinuation every 6 months The Antipsychotic Discontinuation in Alzheimer Disease Trial Randomization of responders to open treatment Patients who met criteria for response at 16 weeks: 30% decline in NPI core scores with CGI-C score of 1 (improved) or much improved (2) rated on psychosis/agitation only Double-blind randomized phase 110 of 112 responders were randomized Risperidone:Placebo 2:1 ratio from weeks Randomization stratified by presence / absence of psychosis, outpatient / assisted living or nursing home Risperidone (0.25 to 3 mg daily) maintained at end-open treatment phase dose (mean 0.97 SD 0.74 mg per day) into the randomized phase
8 Relapse in final 16 weeks after randomization Both time to relapse and risk of relapse favored risperidone over placebo Survival analysis: log-rank test Relative Hazards ratio: 4.88, 95% CI , p=0.023 Relapse rates 48% (13/27) relapsed on placebo 15% (2/13) relapsed on risperidone Chisq=4.33, p=0.017 Action Plan Achieving global recognition of geriatric psychiatry as a subspecialty. Promotion and accreditation of national or international education programs. Both 16-week time periods: no effect of nursing home/outpatient or psychosis status LIA FERNANDES, 2015 Action Plan Promotion and financing of international exchange of geriatric psychiatry programs (at graduate and postgraduate levels). Collaboration on international research networks, particularly with IPA affiliates, the EAGP, and the WHO. Helping the affiliate organizations in countries with less developed psychogeriatrics, with support of research funding (e.g. grants and fellowships). Promotion of research in geriatric psychiatry with projects possibly led by IPA and aiming for identification of the best patient for the best treatment at the best time. Action Plan Sharing with former pioneers references, the expertise for consultation and education in local trainings. Participation of international opinion leaders in education and scientific conferences, continuing medical education (CME) programs, subspecialty training courses, and online education. IPA should act as an international leader in psychogeriatrics in international forums related to mental health of the elderly. Advocacy to influence the political process to improve mental health services for older people and strengthen national associations and their members with financial support LIA FERNANDES,2015 LIA FERNANDES
9 Conclusion We need to have the right professionals find the right patient and provide: The right treatment/medication At the right time At the right dose
Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationAntipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses
658463TAJ0010.1177/2040622316658463Therapeutic Advances in Chronic DiseaseRR Tampi, DJ Tampi research-article2016 Therapeutic Advances in Chronic Disease Original Research Antipsychotic use in dementia:
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationUSING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University
More information11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationTRANSPARENCY COMMITTEE Opinion 19 February 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the
More informationManaging agitation in dementia using non-pharmacological therapies
Managing agitation in dementia using non-pharmacological therapies Gill Livingston Lynsey Kelly, Elanor Lewis-Holmes, Gianluca Baio, Rumana Omar, Stephen Morris, Nishma Patel, Cornelius Katona, Claudia
More informationBPSD%What&to&do?&& Geriatric&Refresher&Day&& 11:30#12:30,&Wed&March&4 th,&2015& St&Elias&Centre,&OCawa&Ontario& &
RGPEO% Regional&Geriatric&Program&of&Eastern&Ontario& BPSD%What&to&do?&& Geriatric&Refresher&Day&& 11:30#12:30,&Wed&March&4 th,&2015& St&Elias&Centre,&OCawa&Ontario& & Behavioural&and& Psychological& Symptoms&&
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationPrediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer s Disease: The Role of Hallucinations
ARTICLES Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer s Disease: The Role of Hallucinations Anjali N. Patel, D.O., Seonjoo Lee, Ph.D., Howard F. Andrews, Ph.D., Gregory
More information9: 3 TABLE OF CONTENTS P&T
Vol 9: No 3 TABLE OF CONTENTS Short-term Safety of Antipsychotics for Dementia 1-2 Preoperative Statins and Effects on Mortality 2-4 Hormone Replacement Therapy and Risk of Venous Thromboembolism 4-5 P&T
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationThe Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias
The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias The Patient and Carers Perspective Mary-Frances Morris, Trustee, Alzheimer Scotland.
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationDainippon Sumitomo Pharma
Progressing Towards an Internationally Competitive R&D-Oriented Pharmaceutical Company Dainippon Sumitomo Pharma Masayo Tada President and CEO 29th Annual J.P. Morgan Healthcare Conference January 11,
More informationPDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version
PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version www.pdflib.com sales@pdflib.com doi:10.1111/j.1479-8301.2007.00215.x PSYCHOGERIATRICS 2008; 8: 32 37 REVIEW
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationRe: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl capsules) Hyperglycemia, Weight Gain, and Hyperlipidemia
www.lilly.com Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. Phone 317 276 2000 October 5, 2007 Re: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationHealth authorities are asking for PRO assessment in dossiers From rejection to recognition of PRO
UNDERSTANDING AND ADDRESSING POTENTIAL BIAS IN PATIENT-REPORTED OUTCOMES FROM CLINICAL TRIALS ISPOR Barcelona Workshop Tuesday 13 November 14:00-15:00 Prof. Olivier Chassany EA 7334, Patient-Centered Outcomes
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationOBJECTIVES. Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia
Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia Amy J. Osborn, NHA, PMP Executive Director, Health Services Advisory Group (HSAG) Rick Foley, PharmD,
More informationRelapse Risk after Discontinuation of Risperidone in Alzheimer s Disease
original article Relapse Risk after Discontinuation of Risperidone in Alzheimer s Disease D.P. Devanand, M.D., Jacobo Mintzer, M.D., M.B.A., Susan K. Schultz, M.D., Howard F. Andrews, Ph.D., David L. Sultzer,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNetwork Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications
Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications JOHN M. DAVIS, MD Professor of Psychiatry University of Illinois at Chicago Chicago, Illinois and STEFAN LEUCHT, MD Klinik
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationAtypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study
Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Stewart G. Albert, MD, George T. Grossberg, MD, Papan J. Thaipisuttikul,
More informationAgenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK
Agenda 2030: One Nation Labour s Plan for science Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research charity. As research experts,
More informationClinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India
Indian J Psychiatry. 2009 Oct-Dec;; 51(4): 272 275. doi: 10.4103/0019-5545.58292 PMCID: PMC2802374 Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India 1
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationBaseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients
Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients Robert Howard MD MRCPsych, Professor of Old Age Psychiatry
More informationTrial clinici nell anziano: efficacy or effectiveness?
LA SPERIMENTAZIONE FARMACOLOGICA CLINICA IN ETÀ GERIATRICA Trial clinici nell anziano: efficacy or effectiveness? Graziano Onder Fondazione Universitaria Policlinico A. Gemelli Università Cattolica del
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationNeuropsychiatric Syndromes
Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationCLERI<'SA~~~~~~~~: COURT FILED
Case 1:12-cr-00026-SGW Document 5-2 Filed 05/07/12 Page 1 of 24 Pageid#: 31 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF VIRGINIA ABINGDON DIVISION CLERI
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationAntipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia Number Needed to Harm
Research Original Investigation Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia Number Needed to Harm Donovan T. Maust, MD, MS; Hyungjin Myra Kim, ScD; Lisa S. Seyfried,
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationLeadingAge and Hospice Members: Partners in Providing Quality Care to Older Adults. January 2019
LeadingAge and Hospice Members: Partners in Providing Quality Care to Older Adults January 2019 Hospice is a unique service delivery model providing holistic care to individuals at the end of their lives.
More informationAntipsychotic Medications in the Treatment of Dementia with Behavior Disturbance
Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance American Association for Geriatric Psychiatry Los Angeles, CA March 2013 Maureen C. Nash, MD, MS, FAPA Medical Director,
More informationTreatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationRisperidone use in children with autism carries heavy risks
NEWS Risperidone use in children with autism carries heavy risks BY EMILY ANTHES 28 APRIL 2014 1 / 6 Double edge: Risperidone can calm tantrums and aggression in some children with autism, but sleepiness
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationMANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 1 February 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 1 February 2012 XEPLION 25 mg, prolonged-release suspension for injection 1 pre-filled polycycloolefin syringe with
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this
More informationMental Health Subcommittee of PTAC meeting held 21 June (minutes for web publishing)
Mental Health Subcommittee of PTAC meeting held 21 June 2010 (minutes for web publishing) Mental Health Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationRisks of Antipsychotics use In Dementia
AHCA/NCAL Quality Initiative for Assisted Living Webinar Series: Safely Reducing the Off-Label Use of Antipsychotics Risks of Antipsychotics use In Dementia Sanjay P. Singh, MD Chairman & Professor, Department
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationSafety Profile Assessment of Risperidone and Olanzapine in Long-Term Care Patients with Dementia
ORIGINAL STUDIES Safety Profile Assessment of Risperidone and Olanzapine in Long-Term Care Patients with Dementia Harlan Martin, RPh, CCP, FASCP, Michael P. Slyk, PharmD, FASCP, Sheila Deymann, PharmD,
More informationBehavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia
The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 6, Issue 4, DIP: 18.01.090/20180604 DOI: 10.25215/0604.090 http://www.ijip.in October-December, 2018 Research
More informationRole of ADHD medication in children with autism spectrum disorder. Pieter Hoekstra University of Groningen, Netherlands
Role of ADHD medication in children with autism spectrum disorder Pieter Hoekstra University of Groningen, Netherlands Symptoms of ADHD are highly prevalent in children with ASD Two independent chart reviews
More informationNKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information
NKR 55 demens og medicin PICO 2 seponering af antipsykotisk medicin versus forsat behandling Review information Authors Sundhedsstyrelsen 1 1 [Empty affiliation] Citation example: S. NKR 55 demens og medicin
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Howard R, McShane R, Lindesay J, et al. Donepezil and memantine
More informationHandout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes
Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationPsychopharmacology of Autism Spectrum Disorder
Psychopharmacology of Autism Spectrum Disorder Christopher J. McDougle, MD Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral Hospital
More informationEvidence-Based Interventions to Improve Caregiver and Patient Outcomes in Dementia
Evidence-Based Interventions to Improve Caregiver and Patient Outcomes in Dementia Alan B. Stevens, PhD Professor, Department of Medicine Vernon D. Holleman-Lewis M. Rampy Centennial Chair in Gerontology
More informationResponsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease
ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,
More informationFile NDA SE5 046/047, NDA SE5 036/037, NDA SE5 020/021
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: 18 June 2007 FROM: TO: SUBJECT: Mitchell V.
More informationSilvia Duong, 1,2 Kam-Tong Yeung, 1 and Feng Chang 1,3. 1. Introduction
Aging Research Volume 2015, Article ID 570410, 6 pages http://dx.doi.org/10.1155/2015/570410 Research Article Intramuscular Olanzapine in the Management of Behavioral and Psychological Symptoms in Hospitalized
More informationPsychotropics in Learning Disabilities: Systematic reviews. Professor Shoumitro Deb FRCPsych, MD University of Birmingham
Psychotropics in Learning Disabilities: Systematic reviews Professor Shoumitro Deb FRCPsych, MD University of Birmingham HTA EVIDENCE CATEGORIES Type I: RCTs/ Meta analysis Type II: Other controlled studies
More informationManagement of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
More informationPMDA Considerations for Outcome Assessments
PMDA Considerations for Outcome Assessments Keiju Motohashi Office of New Drug II Pharmaceuticals and Medical Devices Agency/ The University of Tokyo Hospital Disclaimer The views and opinions expressed
More informationEffect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
Research Original Investigation Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial Jeffrey L. Cummings, MD, ScD; Constantine G. Lyketsos,
More informationa division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 26 November 2008 Document No.: EDMS-PSDB-9183291 Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-SCH-3001 Janssen-Cilag
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More information